23andMe to delist from Nasdaq, deregister with SEC

23andMe on Tuesday introduced it’s going to voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, in keeping with a unencumber.

The transfer comes after Regeneron Pharmaceuticals mentioned previous this month that it’s going to achieve “substantially all” of 23andMe’s property for $256 million.

The drugmaker got here out on best following a chapter public sale for 23andMe, a as soon as high-flying genetic trying out corporate that filed for for Chapter 11 chapter coverage in March.

This is breaking information. Please refresh for updates.